Compare · FIGS vs SILO
FIGS vs SILO
Side-by-side comparison of FIGS Inc. (FIGS) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FIGS and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- FIGS is the larger of the two at $2.44B, about 537.1x SILO ($4.5M).
- SILO has been more active in the news (8 items in the past 4 weeks vs 6 for FIGS).
- FIGS has more recent analyst coverage (25 ratings vs 0 for SILO).
- Company
- FIGS Inc.
- Silo Pharma Inc.
- Price
- -
- -
- Market cap
- $2.44B
- $4.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 0
FIGS
FIGS Inc.
FIGS, Inc. operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States. It designs and sells healthcare apparel and other non-scrub offerings, such as lab coats, under scrubs, outerwear, activewear, loungewear, compression socks footwear, masks, and face shields. The company markets and sells its products through its digital platform comprising website and mobile app. FIGS, Inc. was founded in 2013 and is headquartered in Santa Monica, California.
Latest FIGS
- Executive Chairman Hasson Heather L. covered exercise/tax liability with 30,142 shares, decreasing direct ownership by 2% to 1,396,852 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Oughtred Sarah covered exercise/tax liability with 21,962 shares, decreasing direct ownership by 2% to 1,088,165 units (SEC Form 4) to cover withholding tax
- Telsey Advisory Group reiterated coverage on FIGS, Inc. with a new price target
- SEC Form 10-Q filed by FIGS Inc.
- FIGS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- FIGS Releases Second Quarter 2026 Financial Results
- FIGS Announces Date of Second Quarter 2026 Earnings Release, Conference Call and Webcast
- Chief Financial Officer Oughtred Sarah covered exercise/tax liability with 22,197 shares, decreasing direct ownership by 2% to 1,110,127 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Spear Catherine Eva covered exercise/tax liability with 61,556 shares, decreasing direct ownership by 3% to 1,733,408 units (SEC Form 4) (for tax liability)
- Executive Chairman Hasson Heather L. covered exercise/tax liability with 6,813 shares, decreasing direct ownership by 0.48% to 1,426,994 units (SEC Form 4) to cover taxes
Latest SILO
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
- Silo Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Silo Pharma Inc.
- Silo Pharma Granted European Patent Covering Novel PTSD Therapy
- SEC Form EFFECT filed by Silo Pharma Inc.
- SEC Form 424B3 filed by Silo Pharma Inc.
- Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
- SEC Form S-8 filed by Silo Pharma Inc.
- SEC Form S-3 filed by Silo Pharma Inc.